A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
| Status: | Recruiting |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 12/26/2018 |
| Start Date: | September 27, 2018 |
| End Date: | December 2019 |
| Contact: | Cherie N Robbins, BScN |
| Email: | clinicaltrialsinfo@anaptysbio.com |
| Phone: | 858-362-6295 |
A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
A study investigating the efficacy and safety, and pharmacokinetic (PK) profile of ANB019 in
subjects with generalized pustular psoriasis
subjects with generalized pustular psoriasis
This is a Phase II single arm multiple dose study to assess the efficacy and safety, and PK
of ANB019 in subjects with Generalized Pustular Psoriasis
of ANB019 in subjects with Generalized Pustular Psoriasis
Inclusion Criteria:
- Diagnosis of active GPP
- Total JDA score of at least moderate severity or erythema with pustules accounting for
at least 10%
- Must be candidates for systemic therapy or phototherapy
Exclusion Criteria:
- Erythrodermic , guttate, drug induced GPP
- Any other ongoing inflammatory disease that interfere with the Investigator's ability
to evaluate the subject's response to therapy
- History of recurrent or chronic infection
- ongoing use of psoriasis prohibited medication
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
2
sites
Click here to add this to my saved trials
